TNGX
TNGX clinical trials: Tango Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Tango Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 7
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
TNGX on the catalyst calendar · TNGX registry changes
- Primary completion Sep 22, 2026ActualPhase 1/Phase 2NCT05887492Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsTango Therapeutics, Inc. · Non Small Cell Lung CancerActive, not recruitingTNGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 1/Phase 2NCT06922591Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsTango Therapeutics, Inc. · PDACRecruitingTNGXLeadRVMDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2031Sponsor estimatePhase 1/Phase 2NCT07897734TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC...Tango Therapeutics, Inc. · PDACNot yet recruitingTNGXLeadERASCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2027Sponsor estimatePhase 1/Phase 2NCT06810544Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossTango Therapeutics, Inc. · Non Small Cell Lung CancerRecruitingTNGXLeadLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 1/Phase 2NCT05732831Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsTango Therapeutics, Inc. · Locally Advanced Solid TumorRecruitingTNGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2025ActualPhase 1/Phase 2NCT05275478Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid TumorsTango Therapeutics, Inc. · Locally Advanced Solid TumorTerminatedTNGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 22, 2024ActualPhase 1/Phase 2NCT06065059Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid TumorsTango Therapeutics, Inc. · Breast CancerTerminatedTNGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2027Sponsor estimatePhase 1NCT07938463Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLCDana-Farber Cancer Institute · ALK Positive Non-small Cell Lung CancerNot yet recruitingTNGXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 1, 2027Sponsor estimatePhase 1/Phase 2NCT06188702S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAPServier Bio-Innovation LLC · MTAP-deleted Solid TumorsActive, not recruitingTNGXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner